Adaptimmune Therapeutics plc (ADAP) is a clinical-stage biotechnology company based in the United Kingdom. The company focuses on developing T-cell therapies to treat cancer. Adaptimmune's proprietary technology platform enables the identification and engineering of T-cell receptors (TCRs) with the potential to target and destroy cancer cells.
Adaptimmune has several TCR therapy candidates in development, including ADP-A2M4 for the treatment of synovial sarcoma and ADP-A2AFP for the treatment of hepatocellular carcinoma. The company's most advanced candidate, ADP-A2M4CD8, is being evaluated in a Phase 1 trial for the treatment of solid tumors.
Adaptimmune has collaborations with several pharmaceutical companies, including GSK, where the company is developing T-cell receptor therapy for multiple cancer targets.
In addition to TCR therapy, Adaptimmune is also developing a next-generation personalized T-cell therapy platform, which utilizes the patient's own T-cells to create personalized therapies.
As of September 2021, Adaptimmune had a market capitalization of approximately $640 million.
|
